CH Biotech R&D CoTPE:6534 +0.33%84 PB Ratio is 3.38 as of Jul. 06, 2026, which is 28% below its 10-year median of 4.69. GuruFocus rates TPE:6534 with a GF Score™ of 84/100 and a GF Value™ of NT$100.55 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 247 Agriculture companies, CH Biotech R&D Co ranks worse than 83.4% on this metric.
The historical rank and industry rank for CH Biotech R&D Co's PB Ratio or its related term are showing as below:
TPE:6534'
s PB Ratio Range Over the Past 10 Years
Min: 2.74 Med: 4.69 Max: 25.72
Current: 3.38
During the past 13 years, CH Biotech R&D Co's highest PB Ratio was 25.72. The lowest was 2.74. And the median was 4.69.
TPE:6534's PB Ratio is ranked worse than 83.4% of 247
companies
in the Agriculture industry
Industry Median: 1.49
vs TPE:6534: 3.38
During the past 12 months, CH Biotech R&D Co's average Book Value Per Share Growth Rate was 3.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 7.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 12.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 16.70% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of CH Biotech R&D Co was 367.00% per year. The lowest was 7.40% per year. And the median was 15.75% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
CH Biotech R&D Co PB Ratio Related Terms
CH Biotech R&D Co PB Ratio Historical Data
* Premium members only.
The historical data trend for CH Biotech R&D Co's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Agricultural Inputs subindustry, CH Biotech R&D Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CH Biotech R&D Co PB Ratio vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, CH Biotech R&D Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where CH Biotech R&D Co's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
CH Biotech R&D Co (TPE:6534) has a PB Ratio of 3.38 as of Jul. 06, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CH Biotech R&D Co and its competitors. This is 28% below median its historical median of 4.69. Over the past decade, CH Biotech R&D Co's PB Ratio has ranged from 2.74 to 25.72. According to the industry distribution chart, CH Biotech R&D Co ranks #206 out of 247 companies in the Agriculture industry, placing it in the top 83.4%.
Is CH Biotech R&D Co's PB Ratio too high?
CH Biotech R&D Co's current PB Ratio of 3.38 is 28% below median its 10-year median of 4.69. Over the past 10 years, this metric has ranged from a low of 2.74 to a high of 25.72. The Agriculture industry median PB Ratio is 1.49. CH Biotech R&D Co's value of 3.38 is 126.8% above this industry median. Based on the distribution chart, CH Biotech R&D Co ranks #206 out of 247 companies in the Agriculture industry, which is in the bottom quartile relative to peers. Overall, CH Biotech R&D Co has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CH Biotech R&D Co's PB Ratio compare to CTVA and CF?
According to the Agriculture industry distribution chart, CH Biotech R&D Co ranks #206 out of 247 companies for PB Ratio. This places CH Biotech R&D Co in the lower half of its industry. The industry median PB Ratio is 1.49. CH Biotech R&D Co's value of 3.38 is 126.8% above this benchmark. Historically, CH Biotech R&D Co's own PB Ratio has ranged from 2.74 to 25.72 over the past decade. While the company's 10-year median is 4.69 vs. the industry median of 1.49, CH Biotech R&D Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for an Agriculture company?
The median PB Ratio among Agriculture companies is 1.49, based on 247 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CH Biotech R&D Co's current PB Ratio of 3.38 is 126.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CH Biotech R&D Co and its competitors. For the Agriculture industry, the median PB Ratio is 1.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CH Biotech R&D Co's current PB Ratio is 3.38, which is 28% below median its own 10-year median of 4.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CH Biotech R&D Co stock overvalued right now?
Based on GuruFocus' analysis, CH Biotech R&D Co (TPE:6534) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$100.55, compared to a current price of NT$90.10 — trading 10.4% below its estimated fair value. The current PB Ratio is 3.38, which is 28% below median its 10-year median of 4.69 and 126.8% above the Agriculture industry median of 1.49. CH Biotech R&D Co's overall GF Score™ is 84/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For CH Biotech R&D Co (TPE:6534), the current PB Ratio is 3.38 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CH Biotech R&D Co (TPE:6534) Overvalued in 2026?
Based on GuruFocus' analysis, CH Biotech R&D Co stock appears to be undervalued.
The current stock price of NT$90.10 is trading 10.4% below its estimated GF Value™ of NT$100.55.
GuruFocus considers CH Biotech R&D Co to be Modestly Undervalued.
Key valuation signals for TPE:6534:
PB Ratio: 3.38 (28% below median its 10-year median of 4.69)
GF Value™: NT$100.55 vs. price of NT$90.10 (10.4% below fair value)
Industry Position: 126.8% above the Agriculture median (#206 of 247)
No single metric tells the full story. See the TPE:6534 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CH Biotech R&D Co Ltd is a Taiwan-based company engaged in the manufacture and sales of fertilizer, as well as providing biotechnology services. It is engaged in the research, development, manufacturing, and sales of proprietary plant growth regulators and specialty micronutrient fertilizers. It offers NutriSync 3D plant growers in the form of boron and molybdenum, NutriSync D liquid formulation for dicot crops, CHB-HS for reducing carbon emissions in crop production, CHB-BB2, fruit quality enhancers, and other related products. The company has one reportable segment, Agricultural Biotechnology. Geographically, it derives maximum revenue from the United States, and the rest from other countries.
84GF Score
Get the complete analysis for TPE:6534
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6534 has been successfully added to your 
